Recently, a retrospective, observational study involving 303 HR+/HER2- patients with advanced BC found that fulvestrant is an effective, safe and well-tolerated ET for HR+/HER2- MBC [13], and it can also be used as a maintenance therapy after first-line palliative chemotherapy. Here, ERBB2 is linked to breast cancer.